Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05847400
Other study ID # ckd in tybe 2 dm
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 1, 2024
Est. completion date April 1, 2024

Study information

Verified date April 2023
Source Assiut University
Contact Muhammed Al Abualsaud
Phone ?+20 106 923 9438?
Email Aboalsaud25@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Predictors of Chronic Kidney Disease among Type 2 Diabetic Patients in Assiut University Hospitals.


Description:

Globally, the total number of people with diabetes is estimated to increase from 415 million (8.8%) in 2015 to 642 million (10.4%) in 2040, with the largest alterations expected to occur in the urban population of low- to middle-income countries (LMICs)1. Of them, type 2 diabetes mellitus (T2DM) accounts for more than 90% of people with diabetes2,3. By 2040, the difference worldwide is projected to broaden, with 477.9 million affected people living in urban areas and 163.9 million in rural areas1. It has been postulated that the burden of diabetes and its complications in the LMICs may be contributed by the economic development and rapid urbanisation via increased caloric intake and the adoption of a sedentary lifestyle2,4,5. More importantly, the most striking demo graphic change to diabetes prevalence in global terms also seems to be related to the growth of the proportion of the elderly population6. Despite rates of diabetes-related complications such as CVDs decreasing significantly in the past two decades, it has not translated nearly as well as kidney complications7. Approximately 10% of deaths in people with T2DM are attributable to kidney failure8. It is well-established that diabetes-related chronic kidney disease (CKD) is the leading cause of end-stage kidney disease (ESKD) in T2DM patients worldwide9,10. In our study, we aim to identify and classify patients attending diabetic outpatient clinic with both CKD and


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date April 1, 2024
Est. primary completion date March 28, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with T2DM aged 18 years or older. For patients whom eGFR values < or =60 ml/min/1.73m2. Patient with type 2 DM and ESRD on regular HD with duration less than 1 year Exclusion Criteria: Having kidney transplantation incomplete data on glycemic control. Patients with type 2 DM and ESRD on regular HD with duration more than 1 year. Pregnant woman. Patients with advanced comorbides(cardiac, hepatic,

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Assiut Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary predictors of CKD among T2DM patients attending Assiut University Hospitals. To classify our patients into stages according to KDIGO guidelines To identify predictors of CKD among T2DM patients attending Assiut University Hospitals.
To classify our patients into stages according to KDIGO guidelines
3 years
Secondary the possible risk factors contributing to progessing CKD in T2DM patients. To identify the possible risk factors contributing to progessing CKD in T2DM patients. 3 years
See also
  Status Clinical Trial Phase
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Not yet recruiting NCT04061200 - Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria Phase 4
Recruiting NCT04216849 - Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy Phase 1/Phase 2